

Correction: *Phase 2 study of pembrolizumab in patients with advanced rare cancers*

Naing A, Meric-Bernstam F, Stephen B, *et al.* Phase 2 study of pembrolizumab in patients with advanced rare cancers. *J Immunother Cancer* 2020;8:e000347. doi: 10.1136/jitc-2019-000347

In the article titled 'Phase 2 study of pembrolizumab in patients with advanced rare cancers', the author name Abulrahman Abonofal is spelt incorrectly. The correct spelling is Abdulrahman Abonofal.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000347corr1. doi:10.1136/jitc-2019-000347corr1

